Chris was invited to review and comment on the new IMC Cost Drivers Analysis of Private Drug Plans in Canada (2016-2019) with a handful of successful benefit consultants, in a series of virtual meetings.  The meeting was intended to get our input on the new data and to answer some focused questions on key findings and topics.